Editing a viral genome is like finding and fixing a single typo in a 200,000-letter book—without leaving any trace you were there. French scientists recently cracked this problem with an ingenious workaround that's making vaccine development much faster.
Vaccinia virus: An old vaccine with new tricks
You've probably never heard of vaccinia virus, but you owe it a debt. This was the virus used in the smallpox vaccine—the one that helped wipe smallpox off the face of the Earth. Billions of people got this vaccine safely.
These days, vaccinia has found new life as a research workhorse. Its large genome can carry up to 25,000 base pairs of foreign DNA, which means scientists can pack it with instructions for multiple disease targets at once. Researchers are testing vaccinia-based vaccines for HIV, flu, COVID-19, and even some cancers.
There's just one problem: editing this virus's genome has always been maddeningly difficult.
The old way was painfully slow.
For years, scientists used a technique called homologous recombination. It worked less than 1% of the time. You'd have to run the same experiment nearly a hundred times to get one successful edit.
To find the rare viruses that actually got edited, researchers added "marker genes"—genetic flags that helped identify success. But these extra genes created safety headaches for vaccines meant for people. The whole process could take weeks or even months for a single change.
CRISPR helped, but not enough
CRISPR/Cas9 changed everything when it arrived. This molecular tool cuts DNA precisely where you tell it to, like programmable scissors. Applied to vaccinia, it pushed success rates above 90% for some edits.
But CRISPR still struggled with the smallest, most delicate changes—swapping a single DNA letter. These tiny tweaks are crucial for understanding exactly how viral proteins work, yet they remain frustratingly hard to pull off.
The clever fix
Here's where the French team got creative. CRISPR needs to recognise a short DNA sequence called a PAM site—think of it as an address label. The researchers realised they could introduce a "silent mutation" into this PAM site that doesn't change the protein it codes for but makes the site invisible to CRISPR.
What happens next is elegant: when you apply CRISPR to a mix of edited and unedited viruses, it only cuts the unedited ones. The edited viruses, now hidden from CRISPR, survive and multiply. The silent mutation also knocked out a restriction enzyme site, letting researchers verify edits with standard lab tests instead of expensive sequencing.
The results speak for themselves.
Testing their approach on the E9L gene (which makes the enzyme that copies viral DNA), the team saw editing efficiency jump from 14% to 70-95%, depending on the target.
They also created viruses resistant to cidofovir, an antiviral drug. Half their isolated samples carried the mutations for strong drug resistance—useful for studying how resistance evolves.
Some mutations turned out to be lethal to the virus, revealing which protein interactions are essential. Even the failures taught them something.
Why this matters
Faster vaccines. With new diseases constantly emerging, cutting vaccine development time from months to two weeks makes a real difference.
Better cancer treatments. Viruses engineered to hunt cancer cells can now be refined more quickly and safely.
Cleaner products. Skipping marker genes means fewer regulatory hurdles and simpler manufacturing.
Deeper understanding. Scientists can now probe individual amino acids to figure out exactly what they do.
What's next
The team wants to explore mysterious regions of the viral DNA polymerase that nobody understands yet—features unique to poxviruses that might reveal new drug targets. The technique should work for other large DNA viruses, too.
The bigger lesson
What's remarkable here isn't that scientists invented some radical new technology. They didn't. They just combined existing tools—CRISPR, PAM biology, standard molecular techniques—in a smarter way.
That's how a lot of scientific progress actually happens. Not through eureka moments, but through clever people asking, "What if we tried it this way instead?"
As we face new pandemics and search for better cancer therapies, we need more innovation like this. Every new vaccine has stories like this behind it—stories of scientific creativity turning the impossible into routine.
Reference: